ClinicalTrials.Veeva

Menu

The Russian Multicenter Observational Study "Evaluation of the HDQ for the Diagnosis of Hemorrhoidal Disease ( HDQ )

Servier logo

Servier

Status

Enrolling

Conditions

Haemorrhoids

Treatments

Other: Hemorrhoid Disease Questionnaire

Study type

Observational

Funder types

Industry

Identifiers

NCT04943666
IC4-05682-063-RUS

Details and patient eligibility

About

Currently in Russia there is no available self-evaluating tools with appropriate diagnostic accuracy for screening of patients with haemorrhoids. Therefore, the primary objective of this study is to evaluate a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia. Once evaluated, the HDQ will be used in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.

Secondary objectives of the study are to describe a prevalence of haemorrhoids among patients in the study and to describe a prevalence of the symptoms of haemorrhoids among patients in the study

Full description

Main parameters (primary outcomes) to be evaluated in the study are:

  1. sensitivity of the HDQ for screening of patients with haemorrhoids;
  2. specificity of the HDQ for screening of patients with haemorrhoids;

Additional parameters (secondary outcomes) in the study are:

  1. Prevalence rate of haemorrhoids among study population established by physicians basing on the results of the objective examination;
  2. Prevalence of the symptoms of haemorrhoids among patients in the study

Enrollment

450 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The patient came to visit a coloproctologist
  • Male or female aged over 18 years
  • Signed informed consent form to participate in the study has been obtained
  • Absence of conditions requiring emergency medical care.
  • The patient is not taking VAD for at least 1 month before the date on inclusion to the study

Exclusion criteria

  • Confirmed or suspected malignant tumor
  • Diagnosed coloproctological disease at the time of inclusion
  • Severe somatic disorders (of heart and blood vessels, lungs, kidneys, pancreas, or liver), associated with decompensation of organ functions
  • Mental disorders
  • Presence of contraindications for examination

Trial contacts and locations

1

Loading...

Central trial contact

Olga Linnik

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems